Janssen

DARZALEX FASPRO

View Prices
  1. Home
    2.  / 
  2. J Code
    3.  / DARZALEX FASPRO – J9144

Manufacturer:

Janssen

Name:

DARZALEX FASPRO

HCPCS Code Descriptor:

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Category:

J Code

HCPCS:

J9144

NDC(s):

57894-0503-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Subcutaneous

About:

DARZALEX FASPRO is an Oncology drug manufactured by Janssen and administered via the Subcutaneous route of administration. The J Code: J9144 is aligned to the drug DARZALEX FASPRO.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

1/1/21

HCPCS Effective Date:

1/1/21

HCPCS Short Description:

Daratumumab, hyaluronidase

Billing and Coding Guide:

https://www.janssencarepath.com/hcp/sites/www.janssencarepath-v2.com.hcp/files/darzalex-faspro-reimbursement-and-access-guide.pdf?v=128

Patient Assistance:

Not Found